Second Line Capital »

Intellia Therapeutics shares owned by Second Line Capital

Quarter-by-quarter ownership of Intellia Therapeutics (NTLA) shares owned by Second Line Capital from 13F filings

Historical chart of Second Line Capital investment in Intellia Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Intellia Therapeutics held by Second Line Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intellia Therapeutics by Second Line Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.1M 63k 17.27
2025-06-30 $591k 63k 9.38
2025-03-31 $567k 80k 7.11
2024-12-31 $1.5M 131k 11.66

More positions owned by Second Line Capital

Etf Ser Solutions Aptus Collrd Inv (ACIO)
Etf Ser Solutions Aptus Defined (DRSK)
Etf Ser Solutions Aptus Int Enh Yl (IDUB)
Spdr Index Shs Fds Portfolio Devlpd (SPDW)
Etf Ser Solutions Aptus Drawdown (ADME)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Etf Ser Solutions Opus Sml Cp Vl (OSCV)
Etf Ser Solutions Aptus Enhanced (JUCY)
Applovin Corp Com Cl A (APP)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Etf Ser Solutions Aptus Large Cap (DUBS)
Spdr Index Shs Fds Portfolio Emg Mk (SPEM)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
First Tr Exchange-traded First Tr Enh New (FTSM)

View all positions for Second Line Capital

Top funds holding Intellia Therapeutics

ARK Investment Management
Vanguard Group
BlackRock
Contrarius Group Holdings
State Street Corporation
Goldman Sachs Group
Morgan Stanley
Regeneron Pharmaceuticals
Baker Bros. Advisors
Geode Capital Management
Two Sigma Investments
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
D. E. Shaw & Co
Two Sigma Advisers

View all funds holding Intellia Therapeutics